市場調査レポート

世界の細胞療法市場およびパイプライン動向

Global Cell Therapy Market & Pipeline Insight

発行 KuicK Research 商品コード 302594
出版日 ページ情報 英文 500 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=102.85円で換算しております。

ご注意: DRM (デジタル著作権管理システム) 付PDFになります。制限内容はお問合せください。
Multi-User License: 会社全体での使用権

Back to Top
世界の細胞療法市場およびパイプライン動向 Global Cell Therapy Market & Pipeline Insight
出版日: 2014年02月01日 ページ情報: 英文 500 Pages
概要

世界の細胞療法市場は2012年に25億米ドルに近づく規模になりました。同分野の絶え間ない進化、発展によって、同市場は今後も20〜22%という高い成長率で伸び続け、2018年までに80億米ドルになると予測されています。また細胞療法に関する複数の製品や技術が研究開発パイプラインにあり、2018年までに上市される見込みです。

当レポートでは、世界の細胞療法市場の概要と市場動向、パイプラインの概要とともに、参入する企業の競合環境をまとめ、概略下記の構成で取り上げております。

第1章 細胞療法のイントロダクション

第2章 世界の細胞療法市場概要

  • セグメント別市場
  • 適応別市場
  • 地域別市場分析
  • 市場動向
  • 細胞療法パイプライン

第3章 世界の細胞療法市場動向

  • 市場促進因子
  • 解決すべき課題
  • 将来の成長機会

第4章 細胞療法の主な発展動向

  • 自家細胞から同種細胞療法への移行
  • 克服すべき細胞採取の問題
  • 製造リスクの低減

第5章 相、国、標的とする適応別パイプライン

  • 登録まで進んでいる研究動向
  • 上市済み細胞療法薬剤
  • 中止・中断された薬剤

第6章 相、国、標的とする適応別膵β細胞置換療法パイプライン

  • 登録まで進んでいる研究動向
  • 中止・中断された薬剤

第7章 相、国、標的とする適応別ドーパミン作動性細胞置換療法パイプライン

  • 登録まで進んでいる研究動向
  • 中止・中断された薬剤

第8章 競合環境

  • Amgen
  • Advanced Cell Technology
  • Celgene Corporation
  • Cytomedix
  • California Stem Cell
  • Fibrocell Science
  • Genzyme
  • NeoStem
  • Novartis
  • Stemedica Cell Technologies

図表

目次

Research in cell therapy is transforming the future of medicine. As the life of a human being begins as a cell, these cells undergo a highly complex set of events and finally those few stem become capable of self-renewal and differentiation and develop into the specialized cells in the body. Cell therapy research also offers significant potential for restructuring the method of medical practice.

Since the past 3-5 years, a more complex therapeutic modality has been is emerging as cell therapies which have been developed to treat diseases which are not amenable to treatment with more classical pharmaceutical or biopharmaceutical products. This market offers the promise of successfully regenerating damaged tissues and organs in the body by replacing the damaged tissue and/or by stimulating the body's own repair mechanisms to heal previously irreparable tissues. With their rising popularity, these therapies are becoming more cost effective and efficient.

The global market for cell therapy was valued at close to USD 2.5 Billion in 2012. With continuous advances and developments in this field of medicine, the global cell therapy market is expected to grow at a high rate of 20-22% to reach approximately USD 8 Billion by 2018. Several products and technologies of cell-based therapies are in the R&D pipeline are expected to enter the market during the forecast period, thus resulting in an increased growth rate. It is most likely that the new improved technologies would revolutionize the area of bio-pharma and personalized medicine. Development of sophisticated automation devices for cell expansion and culture process for use in the treatment is one of the emerging trends of ACT market.

With the cell-based therapies growing by leaps and bounds, it is expected that the future years would witness significant advancements in technology in the cell therapy market. Increasing incidence of diseases along with lack of adequate effective treatment for these diseases is most likely to drive the cell therapy technology in developed and developing nations. Among the emerging trends of the global market, the most prominent one is the development of sophisticated automation devices for cell expansion and culture process which could be used in the treatment of life threatening diseases.

"Global Cell Therapy Market & Pipeline Insight" Report Highlights & Findings:

  • Introduction to Cell therapy
  • Global Cell Therapy Market Overview
  • Global Cell Therapy Market Dynamics
  • Cell Therapy Pipeline by Phase, Country & Target Indications
  • Cell Therapy Drugs in Pipeline: More Than 200
  • Highest Number of Drugs in Preclinical Stage: 73
  • Number of Drugs in Phase I/II Stage: 35
  • Key Market: US
  • Majority Cell therapies For Cancer Treatment

Table of Contents

1. Introduction to Cell Therapy

  • 1.1. Origin of Cell Therapy
  • 1.2. The Process of Cell Therapy

2. Global Cell Therapy Market Overview

  • 2.1. Cell Therapy Market by Segments
  • 2.2. Cell Therapy Market by Indications
  • 2.3. Regional Market Analysis
  • 2.4. Market Trends
  • 2.5. Cell Therapy Pipeline

3. Global Cell Therapy Market Dynamics

  • 3.1. Favorable Market Drivers
  • 3.2. Challenges to be Resolved
  • 3.3. Future Growth Opportunity

4. Cell Therapy Key Developments

  • 4.1. Shift from Autologous to Allogeneic Cell Therapies
  • 4.2. Cell Collection Challenges to be Overcome
  • 4.3. Reducing Manufacturing Risk

5. Cell Therapy Pipeline by Phase, Country & Target Indications

  • 5.1. Research till Registration
  • 5.2. Marketed Cell Therapy Drugs
  • 5.3. Discontinued & Suspended

6. Pancreatic Beta Cell Replacements Therapy Pipeline by Phase, Country & Target Indications

  • 6.1. Research till Registration
  • 6.2. Discontinued & Suspended

7. Dopaminergic Cell Replacements Therapy Pipeline by Phase, Country & Target Indications

  • 7.1. Research till Registration
  • 7.2. Discontinued & Suspended

8. Competitive Landscape

  • 8.1. Amgen
  • 8.2. Advanced Cell Technology
  • 8.3. Celgene Corporation
  • 8.4. Cytomedix
  • 8.5. California Stem Cell
  • 8.6. Fibrocell Science
  • 8.7. Genzyme
  • 8.8. NeoStem
  • 8.9. Novartis
  • 8.10. Stemedica Cell Technologies

List of Figures

  • Figure 1-1: The Four Pillars of Global Pharmaceutical Industry
  • Figure 1-2: Composition of Cell Therapy
  • Figure 2-1: Global Cell Therapy Market (US$ Billion), 2012-2018
  • Figure 2-2: Global Cell Therapy Market by Indications, 2013
  • Figure 2-3: Global Cell Therapy Market by Region (%), 2013 & 2018
  • Figure 2-4: Global Cell Therapy Drug Pipeline by Phase(%), 2014
  • Figure 2-5: Global Cell Therapy Drug Pipeline by Phase (Number of Drugs), 2014
  • Figure 2-6: Pancreatic Beta Cell Replacement Therapy Pipeline by Phase (%), 2014
  • Figure 2-7: Pancreatic Beta Cell Replacement Therapy Pipeline by Phase (Number of Drugs, 2014
  • Figure 2-8: Dopaminergic Cell Replacement Therapy Pipeline by Phase (%), 2014
  • Figure 2-9: Dopaminergic Cell Replacement Therapy Pipeline by Phase (Number of Drugs), 2014

List of Tables

Following Information for Each Peptide Profile is Covered in More than 400 Tables in Report:

  • Drug Profile Overview
  • Active Indication
  • Phase of Development
  • Country for Clinical Trial
  • Owner / Originator/ Licensee/Collaborator
  • Administrative Route
  • Drug Class
Back to Top